Amarantus appoints board member
This article was originally published in Scrip
Executive Summary
Amarantus BioScience, which develops treatments and diagnostics for neurodegeneration and apoptosis diseases, has named Mark Benedyk to its board of directors. Dr Benedyk has severed as a corporate advisor to Sunnyvale, California-based Amarantus since 2011. Dr Benedyk is currently a managing partner at business and corporate development consultancy, Rila Partners. He serves on the strategic advisory board of KemPharm, is a director at the Center for Drug Research and Development Ventures and is a member of the translational medicine advisory board of the CNS Regenerative Medicine Foundation. With the addition of Dr Benedyk, Amarantus has four board members.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.